Revolutionizing Weight Loss: Hanmi Pharmaceuticals Unveils Groundbreaking Obesity Treatment at American Society for the Study of Obesity in November
Hanmi Pharmaceutical Unveils New Concept Obesity Treatment at Obesity Week
Hanmi Pharmaceutical is set to unveil a new concept obesity treatment that overcomes the limitations of existing treatments that accompany muscle loss during weight loss at the American Society for the Study of Obesity (Obesity Week) in November.
The ‘HOP (Hanmi Obesity Pipeline)’ project, launched in September last year, is Hanmi Pharmaceutical’s core project that introduces various ‘tailored treatments’ to help in the entire treatment cycle of obesity.
Hanmi Pharmaceutical will disclose the target and non-clinical research results of a new concept obesity treatment candidate substance at the American Society for the Study of Obesity in November. This undisclosed pipeline is expected to dramatically improve the quality of weight loss not only with incretin combination but also as a monotherapy.
Efpeglenatide, the first to start clinical trials as the leader of the HOP project, is currently progressing smoothly in domestic phase 3 clinical trials. Efpeglenatide is being developed as a ’Korean-tailored obesity treatment’ that reflects the body type and weight of Koreans, and has a clear difference from drugs from global pharmaceutical companies.
HM15275, a next-generation innovative obesity treatment following efpeglenatide, is expected to have a weight loss effect of more than 25% while minimizing muscle loss. It is specialized in treating obesity by optimizing the actions of each of the three receptors: GLP-1, gastric inhibitory peptide (GIP), and glucagon (GCG).
Through the HOP project, Hanmi is committed to developing products that can correct the lifestyles and medication compliance of obese patients, such as oral obesity treatments and digital therapeutics that can be applied to obesity prevention and management.
A Hanmi Pharmaceutical official said, “We understand that the market has high expectations for Hanmi Pharmaceutical as it is the most advanced company among domestic pharmaceutical and bio companies not only in terms of the timing of the launch of a new obesity drug but also in terms of research and know-how in the development of treatments for obesity and metabolic diseases.”
Choi In-young, head of Hanmi Pharm’s R&D Center, said, “The second half of this year is an important time to showcase our research achievements on the global stage. The new concept obesity treatment candidate that will be unveiled for the first time at the American Society for the Study of Obesity will not only present a new paradigm for obesity treatment as a monotherapy, but is also designed to be used in combination with existing treatments, making it a game changer that can prove HOP’s global competitiveness.”
Related Topics:
- Obesity Treatment
- Weight Loss
- Muscle Gain
- GLP-1
- Hanmi Pharmaceutical
- HOP Project